Acceptance and Commitment Therapy for Stem Cell Transplant

(ACTivate Trial)

This trial explores whether Acceptance and Commitment Therapy (ACT) can assist individuals undergoing stem cell transplants in managing physical and emotional challenges. ACT is a therapy that encourages individuals to focus on actions that may enhance well-being, even in the face of discomfort. The trial includes two groups: one will receive ACT sessions, while the other will participate in an education control group. Individuals planning to undergo a stem cell transplant in about a month and who have access to a computer or smartphone may be suitable candidates. As an unphased trial, this study provides a unique opportunity to explore innovative therapy options that could enhance the transplant experience.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that Acceptance and Commitment Therapy (ACT) is generally safe for individuals undergoing a hematopoietic stem cell transplant (HCT). Studies have found that ACT does not increase negative side effects, meaning patients did not encounter additional problems with this therapy. ACT, a mindfulness-based treatment, helps reduce stress and enhance mental well-being during treatment.

Unlike traditional treatments for managing the emotional challenges of stem cell transplantation, which often involve medication or standard talk therapy, Acceptance and Commitment Therapy (ACT) focuses on psychological flexibility. This approach encourages patients to accept their thoughts and feelings rather than fighting them, and commit to personal values to guide their actions. Researchers are excited about ACT because it empowers individuals to better handle the emotional stress associated with stem cell transplants, potentially leading to improved mental health outcomes without relying solely on pharmaceuticals.

Research has shown that Acceptance and Commitment Therapy (ACT) can enhance physical abilities in patients undergoing a hematopoietic stem cell transplant (HCT). In this trial, participants in the ACTivate arm will attend sessions based on ACT principles. Studies have found that ACT reduces stress and encourages patients to remain active, even when discomfort arises. Early results suggest that ACT suits HCT patients, as they are willing and able to engage with this therapy. Overall, ACT appears promising in easing the transplant process by improving patients' adaptability and coping skills.³⁴⁵⁶⁷